



Association of Community Cancer Centers

ONCOLOGY ISSUES

The Official Journal of the
Association of Community Cancer Centers

Editor-In-Chief

Sibel Blau, MD

Executive Director

Christian G. Downs, JD, MHA

Chief Medical Officer

Leigh Boehmer, PharmD, BCOP

Managing Editor

Monique J. Marino

Associate Editors

Barbara Gabriel

Maddelynn Parker

EDITORIAL BOARD

Jennifer Bires, LICSW

Stephen Cattaneo, MD

Linda Corrigan, MHE, RHIT, CTR

Sarah Hudson-Disalle, PharmD, RPh

Jeff Hunnicutt

Bridget LeGrazie, APN

Anne Marie F. Rainey

Kelay Trentham, MS, RDN, CSO

Gretchen Van Dyck

Jenna VanGilder, MHA, RN, OCN, CENP

ACCC EXECUTIVE COMMITTEE

President

David R. Penberthy, MD, MBA

President-Elect

Olalekan Ajayi, PharmD, MBA

Treasurer

Nadine J. Barrett, PhD, MA, MS

Secretary

Una Hopkins, RN, FNP-BC, DNP

Past President

Krista Nelson, MSW, LCSW, OSW-C, FAOSW

ACCC Board of Trustees

Robert R. Buras, MD

Amy Ellis

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Pablo Gutman, MD, MBA

Ginah Nightingale, PharmD, BCOP

Lailea Noel, PhD, MSW

Lori Schneider

Leigha Senter-Jamieson, MS, CGC

David Spigel, MD

Wendi Waugh, BS, RT(R)(T), CMD, CTR

Oncology Issues serves the multidisciplinary specialty of oncology care and cancer program management.

Oncology Issues (ISSN: 1046-3356) is published bimonthly for a total of 6 issues per year by Taylor & Francis Group, LLC, 530 Walnut Street, Suite 850, Philadelphia, PA 19106, on behalf of the Association of Community Cancer Centers (ACCC), 1801 Research Blvd, Suite 400, Rockville, MD 20850-3184, USA. US Postmaster: Please send address changes to *Oncology Issues*, c/o The Sheridan Press, PO Box 465, Hanover, PA 17331. Copyright © 2022 by the Association of Community Cancer Centers. All rights reserved. No part of this publication may be reproduced, stored, transmitted, or disseminated in any form or by any means without prior written permission from the publisher, Taylor & Francis Group, LLC.

FROM THE EDITOR

Reflections on the EOM

BY SIBEL BLAU, MD



The Center for Medicare & Medicaid Innovation (the Innovation Center) June 27, 2022, announcement of the Enhancing Oncology Model (EOM), successor to the recently

completed Oncology Care Model (OCM), was much anticipated. The EOM is a five-year voluntary payment model set to begin on July 1, 2023. Under the EOM, participating oncology practices will take on financial and performance accountability for the total cost of episodes of care for chemotherapy to patients with seven common cancer types; two-sided financial risk arrangements are mandatory. (For an EOM-OCM comparison, turn to page 6.)

The Quality Cancer Care Alliance Network (QCCA) is a clinically integrated network of independent community oncology practices. Many QCCA members were highly successful OCM participants, and the program's Monthly Enhanced Oncology Services (MEOS) payments supported practice transformation, the use of shared data analytic tools, best practices, and the development of value-based care pathways. The yearlong interruption between the end of the OCM and the start of the EOM is disappointing to many oncology practices that committed to establishing infrastructure and staffing to support value-based care; many are now financially challenged to continue this support.

QCCA members and the newly formed Exigent Research, a coalition of QCCA practices and practices participating in the National Cancer Care Alliance, met in sunny Seattle in August 2022 for a comprehensive EOM session with subject matter experts, including Alex Chong, PhD, MA, a health insurance specialist for the Innovation Center. Following this session, member practices attended a closed-door meeting to discuss the model. Although practices were excited that value-based care is here to stay, reception of the OEM was "lukewarm." Here are some of our concerns.

The MEOS payments are much lower, and it will be challenging for many practices to support and grow the robust structure necessary to be successful under the EOM.

Two-sided risk from the onset of the EOM is unsettling. At the August meeting, experts and practice leaders discussed the term "risk." Oncology providers are moving toward precision medicine much faster than payers, and pricing a disease might be difficult due to heterogeneity within the same type of cancer. Take, for example, triple-negative breast cancer where treatment may vary from low-dose, short-course chemotherapy to multi-targeted chemo-immunotherapy with high toxicities. Determining the correct target price will be challenging.

Benchmarking is another concern. Some practices with historically well-run, value-based care programs did not perform well in the OCM simply because their benchmark was too low from the start. Practices that improved and did well in the OCM may encounter a similar issue under the EOM.

To succeed under the EOM, practices will need to be proactive. Implementation of technology like ePROs (electronic patient-reported outcomes) will help reduce emergency department admissions and improve patient care, yet technology solutions come with costs that may not be recouped with the lower MEOS payments.

Biosimilars will also play a role in savings like they did in the OCM. An active drug utilization program is a must and should be started now in any practice that has yet to do so.

Developing new processes in care management will also need to start early. OCM practices will need to teach non-OCM practices. QCCA practices shared analytic data during the OCM that tremendously helped others understand their weaknesses and make corrections in a timely manner.

Physician, nursing, administration, and social work leadership will be key. QCCA practices will start a taskforce of these leaders to analyze practice data and assess the viability of the EOM.

Though almost all QCCA practices plan to apply for the EOM, most are unsure whether they will follow through. Before practices can make that decision, we need more data analysis, and we must continue to proactively improve without disrupting our clinic flow and patient care.